NDAORALTABLETPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
Priority Review
NUPLAZID (pimavanserin tartrate) by Acadia Pharmaceuticals is unclear. Approved for parkinson's disease psychosis. First approved in 2016.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUPLAZID (pimavanserin tartrate) is an oral tablet antipsychotic approved in April 2016 for treating hallucinations and delusions associated with Parkinson's disease psychosis. The drug works primarily through inverse agonist and antagonist activity at serotonin 5-HT2A receptors, with secondary effects at 5-HT2C receptors. It represents the first FDA-approved treatment specifically indicated for this neuropsychiatric complication of Parkinson's disease and fills a significant unmet need in a patient population where traditional antipsychotics carry substantial risks.
$0.6BPart D
11.4 years to LOEMechanism of Action
unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.
Indications (1)
Why This Matters for Your Career
Worked on NUPLAZID at Acadia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.